Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Kowa, Kitasato Institute Team Up for Research of Infectious Disease Meds; Cepharanthine for COVID-19
March 24, 2021
- Shionogi Partner BioAge Begins US PII Study for COVID-19 Drug
March 24, 2021
- Taiho Files Antiemetic Fosnetupitant for Japan Approval
March 24, 2021
- Taisho Seeks Japan Approval for Anti-TNFα Nanobody Ozoralizumab
March 23, 2021
- Otsuka Files Tolvaptan Prodrug OPC-61815 in Japan
March 23, 2021
- Daiichi Sankyo Begins Japan PI/II for mRNA COVID-19 Vaccine
March 23, 2021
- KM Biologics Kicks Off Japan PI/II for COVID-19 Vaccine
March 23, 2021
- Eisai Starts Construction of New Injectable/Research Building in Gifu Pref.
March 23, 2021
- Japan Approves 3rd CAR-T Cell Therapy, Celgene’s Breyanzi
March 23, 2021
- ASKA Aims for 70 Billion Yen Sales by FY2025 on Growth of OB-GYN, Thyroid Spaces: New Biz Plan
March 23, 2021
- Takecab OD Tablet Filed in Japan: Takeda/Otsuka
March 23, 2021
- Lenvima/Keytruda Combo Cuts Risk of Death by 38% in Endometrial Cancer
March 22, 2021
- KM Biologics Begins Formulation of AstraZeneca’s COVID-19 Vaccine
March 22, 2021
- Takeda’s OTC Unit to Be Renamed Alinamin with New Chief from Blackstone
March 22, 2021
- Nippon Shinyaku Gets Japan Rights to Menarini’s Blood Cancer Med
March 19, 2021
- Takeda Rolls Out Music App to Encourage Exercise for Parkinson’s Patients
March 18, 2021
- PII Study Now underway for StemRIM’s Redasemtide for Chronic Liver Disease
March 18, 2021
- Medicago/GSK Begins PIII for COVID-19 Vaccine, Mitsubishi Mum on Japan Plan
March 18, 2021
- Eisai, German Institute Link Arms on Neurodegenerative Disorder Research
March 18, 2021
- Torii Gets Japan Rights to Verrica’s Wart Drug
March 18, 2021
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…